Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
131003-88-6
|
| gptkbp:effect |
blocks adenosine A2A receptor activity
|
| gptkbp:hasInChIKey |
QJQYQJXKQKJQKQ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H16N6O2
|
| gptkbp:hasSMILES |
c1cc(c(cc1CCNC2=NC(=NN3C2=NC(=N3)N)c4ccco4)N)O
|
| gptkbp:heldBy |
adenosine A2A receptor antagonist
|
| https://www.w3.org/2000/01/rdf-schema#label |
ZM-241385
|
| gptkbp:is_not_approved_for_clinical_use |
true
|
| gptkbp:is_used_in_research_on |
gptkb:Parkinson's_disease
cognition cardiovascular system neuroprotection |
| gptkbp:IUPACName |
4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino]ethyl)phenol
|
| gptkbp:molecularWeight |
336.35 g/mol
|
| gptkbp:PubChem_CID |
5311107
4470702 CHEMBL23353 |
| gptkbp:referencedIn |
gptkb:ChEMBL
gptkb:PubChem gptkb:ChemSpider |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:adenosine_A2A_receptor
|
| gptkbp:bfsParent |
gptkb:CHEMBL1173605
|
| gptkbp:bfsLayer |
7
|